



**Prof. Dr. Christoph Röllig, MD MSc**

Consultant Hematologist, Head of Clinical Trial Unit, Secretary of SAL Study Group, Universitätsklinikum Dresden.

Christoph Röllig works as consultant haematologist at the University Hospital Dresden, Germany. After his hematology training, he graduated as master in public health at the London School of Hygiene and Tropical Medicine. Christoph Röllig has more than 20 years of clinical experience in hematology, and has published and co-authored more than 150 articles on AML and Multiple Myeloma. He is the coordinating investigator of several Investigator Initiated Trials in AML and the principal investigator in more than 50 clinical trials in AML. He is the first author of German AML guidelines and co-author of the ELN 2022 guidelines on diagnosis and management of AML. Prof. Röllig is coordinating the German Study Alliance Leukemia Study group (SAL), he is a member of Working Group for Clinical Trials at the German Society for Hematology and Oncology (DGHO), member of the Scientific Working Group for AML at the European Haematology Association (EHA) and chairs the AML Working Group of the European LeukemiaNet (ELN).